This company is no longer active
5YX Stock Overview
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Angion Biomedica Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.05 |
| 52 Week High | US$17.10 |
| 52 Week Low | US$6.00 |
| Beta | 0.60 |
| 1 Month Change | 50.83% |
| 3 Month Change | n/a |
| 1 Year Change | -38.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5YX | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 16.0% | 5.8% | 0.6% |
| 1Y | -38.9% | -17.7% | 5.4% |
Return vs Industry: 5YX underperformed the German Pharmaceuticals industry which returned -12.6% over the past year.
Return vs Market: 5YX underperformed the German Market which returned -7.6% over the past year.
Price Volatility
| 5YX volatility | |
|---|---|
| 5YX Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5YX's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 5YX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 8 | Jay Venkatesan | www.angion.com |
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid.
Angion Biomedica Corp. Fundamentals Summary
| 5YX fundamental statistics | |
|---|---|
| Market cap | €27.99m |
| Earnings (TTM) | -€27.05m |
| Revenue (TTM) | €606.90k |
46.1x
P/S Ratio-1.0x
P/E RatioIs 5YX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5YX income statement (TTM) | |
|---|---|
| Revenue | US$653.00k |
| Cost of Revenue | US$6.76m |
| Gross Profit | -US$6.11m |
| Other Expenses | US$23.00m |
| Earnings | -US$29.10m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | -935.07% |
| Net Profit Margin | -4,456.97% |
| Debt/Equity Ratio | 0% |
How did 5YX perform over the long term?
See historical performance and comparison